Blog
Why Is Zions (ZION) Down 6.4% Since Last Earnings Report?
It has been about a month since the last earnings report for Zions (ZION). Shares have lost about 6.4% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the
Why Is Steel Dynamics (STLD) Up 0.5% Since Last Earnings Report?
It has been about a month since the last earnings report for Steel Dynamics (STLD). Shares have added about 0.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend
RLI Corp. (RLI) Up 4.2% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for RLI Corp. (RLI). Shares have added about 4.2% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the
Why Is Cleveland-Cliffs (CLF) Down 16.4% Since Last Earnings Report?
It has been about a month since the last earnings report for Cleveland-Cliffs (CLF). Shares have lost about 16.4% in that time frame, underperforming the S&P 500.
But investors have to be wondering
W.R. Berkley (WRB) Up 3.3% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for W.R. Berkley (WRB). Shares have added about 3.3% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the
BOK Financial (BOKF) Down 1.5% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for BOK Financial (BOKF). Shares have lost about 1.5% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue
Why Is AGNC Investment (AGNC) Up 0.6% Since Last Earnings Report?
It has been about a month since the last earnings report for AGNC Investment (AGNC). Shares have added about 0.6% in that time frame, outperforming the S&P 500.
But investors have to be wondering
Is Innodata Becoming a Critical Data Partner for Big Tech AI?
Innodata’s INOD rapid evolution from a niche data-services provider to a core infrastructure player in the generative AI ecosystem is increasingly evident in its latest results and strategic
RGTI Stock Plunges 41% in a Month: Should Investors Hold or Fold?
Rigetti Computing RGTI has come under renewed pressure, with shares sliding 41% over the past month as investors digest a mix of progress and persistent challenges. The company’s latest earnings
DAL vs. AAL: Which Airline Stock Looks More Promising Now?
Delta Air Lines DAL and American Airlines AAL are two well-known names in the Zacks Transportation- Airline industry. Delta, based in Atlanta, GA, is a founding member of the SkyTeam global airline
BOOT's Omnichannel Strength: Is AI the New Profit Driver?
In the second quarter of fiscal 2026, Boot Barn Holdings, Inc. BOOT demonstrated strength across its omnichannel platform, highlighted by a 14.4% increase in e-commerce same-store sales and
Margins Under Fire: Can NIKE's "Win Now" Actions Bring Long-Term Gains?
NIKE Inc.’s NKE first-quarter fiscal 2026 results show a company fighting through margin pressure while doubling down on its transformation agenda. The sportswear giant’s “Win Now” actions, focused
5 Value Stocks With Compelling Price-to-Sales Ratios & Growth Ahead
Investing in stocks based on valuation metrics is a proven strategy for identifying opportunities with strong upside potential. While the price-to-earnings (P/E) ratio is a popular tool for gauging
Starbucks Down 15% in a Year: Time to Buy the Stock or Stay Cautious?
Starbucks Corporation SBUX has struggled to regain investor confidence, with shares down roughly 15% over the past year. Despite returning to positive same-store sales growth in the latest quarter
NVIDIA Earnings: Key Metrics to Watch
The Q3 earnings cycle continues to roll along, with this week’s reporting docket highlighted by none other than AI poster-child NVIDIA NVDA. The release will wrap up the reporting cycle for the
U.S. Trade Deficit Narrowed in August
Pre-market futures are budding up slightly this morning, in what has become one of the most challenging weeks (so far) in recent memory. Major market indexes have come down since Thursday of last
Target Q3 Earnings Beat Estimates, Sales Decline Amid Soft Traffic
Target Corporation TGT reported third-quarter fiscal 2025 results, with revenues and earnings declining from the prior-year period. While the top line missed the Zacks Consensus Estimate, the bottom
TJX Q3 Earnings and Sales Beat Estimates, Fiscal 2026 Guidance Raised
The TJX Companies, Inc. (TJX) posted third-quarter fiscal 2026 results, wherein the top and bottom lines beat the Zacks Consensus Estimate. Both metrics also increased from the year-ago quarter.
MP Materials' NdPr Production Soars: Can Growth Continue?
MP Materials MP is demonstrating strong growth in rare earth production, with back-to-back solid quarterly performances so far this year. Production of neodymium and praseodymium (NdPr) reached 721
NRG Outperforms Industry in a Year: Buy, Hold or Sell the Stock?
Shares of NRG Energy Inc. NRG have gained 75.5% in the last year compared with the Zacks Utility - Electric Power industry’s rise of 20.2%. The company has also outperformed the Zacks Utilities
JPMorgan Expands in Dubai, Eyes More Business With Mid-Cap Firms
In an effort to do more business with medium-sized companies, JPMorgan JPM is expanding in Dubai, as reported by Reuters. The move by JPM comes at a time when various global financial firms are
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
Insmed INSM announced that the European Commission has approved Brinsupri (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (“NCFB”). Shares of the company were up 2.1% following
IBKR Opens Taipei Exchange Access: Another Step in Global Expansion?
Continuing with its global expansion efforts, Interactive Brokers IBKR recently announced that it has given its clients access to the Taipei Exchange, which is an Asian exchange for shares of small
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
Merck MRK announced that the phase II CADENCE study, which evaluated its newly launched pulmonary arterial hypertension (“PAH”) drug Winrevair, for treating adults with combined post and



